Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

About Wei Zheng

Wei Zheng (郑炜) is an executive director and the vice-chairman of the Board of Wanka Online.

Wei Zheng Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Wei Zheng News

Assessing a compound’s activity, not just its structure, could accelerate drug discovery: Biological activity-based modeling could improve screening for promising drug compounds

Mar 3, 2021

NCATS scientists Ruili Huang, Ph.D., and Wei Zheng, Ph.D., led the research team that created the approach. Their findings were posted online Feb. 23 by the journal Nature Biotechnology. “With this new method, you can find completely new chemical structures based on activity profiles and then develop completely new drugs,” Huang explained. Thus, using information about a compound’s biological activity may expand the pool of promising treatments for a wide range of diseases and conditions. When researchers seek new compounds or look for existing drugs to repurpose against new diseases, they are increasingly using screening tools to predict which drugs might be good candidates. Virtual screening, or VS, allows scientists to use advanced computer analyses to find potentially effective candidates from among millions of compounds in collections. advertisement With BABM, however, researchers don’t need to know a compound’s chemical structure, according to Huang. Instead, they use a profile of a compound’s activity patterns — how it behaves at multiple concentrations against a panel of targets or tests — to predict its potential effectiveness against a new target or in a new drug assay. The now-widespread use of quantitative high-throughput screening (qHTS) allows BABM more accuracy in its predictions. qHTS assesses a compound’s effectiveness at multiple concentrations in thousands of tests over time. That practice provides far more detail about how a compound behaves than does traditional high-throughput screening, which tests only a single concentration of the compound. The information generated by qHTS creates a stronger biological activity profile — also known as a signature — for each one of millions of compounds. To test the BABM approach, the researchers tapped the vast pool of data generated by hundreds of qHTS analyses run on NCATS’ in-house collection of more than 500,000 compounds and drugs. First, they verified BABM’s ability to use activity profiles to identify compounds already shown to be effective against the Zika and Ebola viruses. BABM also identified new compounds that showed promise against those viruses. The scientists then turned to SARS-CoV-2, the virus that causes COVID-19. They applied BABM, a structure-based model and a combined approach to analyze the NCATS library’s compounds to find potential anti-SARS-CoV-2 agents. BABM predicted that the activity profiles of 311 compounds might indicate promise against the coronavirus. The researchers then had an outside laboratory test those 311 compounds against the live SARS-CoV-2 virus. The result: Nearly one-third of the BABM-backed compounds (99) showed antivirus activity in the test. The BABM-driven prediction hit rate topped that of the structure-based model — and combining the activity-based and structure-based models yielded even better predictive results. A key advantage to BABM is speed. “This method is very fast — you essentially just run a computer algorithm, and you can identify many new drug leads, even with new chemical structures,” Huang noted. In fact, screening the entire NCATS library of half a million compounds for anti-SARS-CoV-2 candidates took only a few minutes. BABM also is a transferable tool — it’s not limited to use in the NCATS compound libraries. “Anyone can use this method by applying any biological activity profile data, including publicly available NCATS data,” Huang emphasized. The NCATS researchers predict their activity-based model’s impact could extend far beyond the search for COVID-19 treatments and small-molecule drug discovery. Given any substance with an available activity profile, scientists can predict its activity against a new target, for a new indication, or against a new disease. “In addition to small molecules, this approach can be applied to biologics, antibodies, and other therapies,” Huang said. “BABM is for all drug discovery projects.”

Wei Zheng Acquisitions

1 Acquisition

Wei Zheng acquired 1 company. Their latest acquisition was Beijing Youbei Digital Technology on September 27, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/27/2019

$991

Corporate Majority

3

Date

9/27/2019

Investment Stage

Companies

Valuation

$991

Total Funding

Note

Corporate Majority

Sources

3

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.